European journal of cancer (Oxford, England : 1990) · 2025
Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Debiais Mélanie, Tarabay Anthony, Blanchet-Deverly Sarah, Camilleri Géraldine M, Megherbi Alexandre, Diebakate Laura, Collin Maxime, Hollebecque Antoine, Smolenschi Cristina, Valéry Marine, Pudlarz Thomas, Fuerea Alina Cristina, Boige Valérie, Ducreux Michel, Boilève Alice
Аннотация
BACKGROUND: Metastatic pancreatic adenocarcinoma (mPDAC) has a poor prognosis. FOLFIRINOX (FFX) and gemcitabine nab-paclitaxel (GN) are the preferred first line (L1) regimens. We evaluated real-world outcomes of L1 therapies.
METHODS: Retrospective analysis of all patients who received L1 chemotherapy for mPDAC between 2010 and 2024 at a single academic comprehensive cancer center.
RESULTS: A total of 1012 patients were included: 48 % women, median age 63 years, 91 % ECOG 0-1. Synchronous metastases occurred in 66 % of patients. Liver (67 %), lung (20 %) and peritoneum (20 %) were the most frequent sites of metastasis. L1 regimens were FFX (n = 621, 61 %), gemcitabine (Gem) (141, 14 %), GN (78, 8 %), and others (n = 172, 17 %). Compared with GN, FFX recipients were younger (61 vs 65 years, p < 0.0001) with better ECOG (≥ 2 in 4 % vs 13 %, p < 0.0001). Median OS was 14.5 months (95 %CI [13.3-15.8]) with FFX, 12.4 [9.4-21.9] with GN, 7.9 [6.5-10.7] with Gem and 9.2 [7.2-13.1] with others (p < 0.0001). Respective median PFS were 7.0 months [95 %CI: 6.5-7.9], 5.4 [4.0-8.3], 4.9 [3.6-6.0] and 5.6 [3.6-7.0] (p < 0.05).
CONCLUSIONS: In this large real-world cohort, FFX was associated with superior response rate, PFS, and OS compared with other L1 regimens, supporting its use as standard first-line therapy for mPDAC.
METHODS: Retrospective analysis of all patients who received L1 chemotherapy for mPDAC between 2010 and 2024 at a single academic comprehensive cancer center.
RESULTS: A total of 1012 patients were included: 48 % women, median age 63 years, 91 % ECOG 0-1. Synchronous metastases occurred in 66 % of patients. Liver (67 %), lung (20 %) and peritoneum (20 %) were the most frequent sites of metastasis. L1 regimens were FFX (n = 621, 61 %), gemcitabine (Gem) (141, 14 %), GN (78, 8 %), and others (n = 172, 17 %). Compared with GN, FFX recipients were younger (61 vs 65 years, p < 0.0001) with better ECOG (≥ 2 in 4 % vs 13 %, p < 0.0001). Median OS was 14.5 months (95 %CI [13.3-15.8]) with FFX, 12.4 [9.4-21.9] with GN, 7.9 [6.5-10.7] with Gem and 9.2 [7.2-13.1] with others (p < 0.0001). Respective median PFS were 7.0 months [95 %CI: 6.5-7.9], 5.4 [4.0-8.3], 4.9 [3.6-6.0] and 5.6 [3.6-7.0] (p < 0.05).
CONCLUSIONS: In this large real-world cohort, FFX was associated with superior response rate, PFS, and OS compared with other L1 regimens, supporting its use as standard first-line therapy for mPDAC.